Larimar Therapeutics Inc (NASDAQ: LRMR) kicked off on Thursday, up 3.80% from the previous trading day, before settling in for the closing price of $1.84. Over the past 52 weeks, LRMR has traded in a range of $1.61-$11.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -38.94%. With a float of $36.59 million, this company’s outstanding shares have now reached $63.82 million.
The extent of productivity of a business whose workforce counts for 65 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Larimar Therapeutics Inc (LRMR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Larimar Therapeutics Inc is 42.86%, while institutional ownership is 65.21%.
Larimar Therapeutics Inc (LRMR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.48% during the next five years compared to 50.78% growth over the previous five years of trading.
Larimar Therapeutics Inc (NASDAQ: LRMR) Trading Performance Indicators
Take a look at Larimar Therapeutics Inc’s (LRMR) current performance indicators. Last quarter, stock had a quick ratio of 8.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -2.04 in one year’s time.
Technical Analysis of Larimar Therapeutics Inc (LRMR)
The latest stats from [Larimar Therapeutics Inc, LRMR] show that its last 5-days average volume of 0.63 million was inferior to 0.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 63.84%. Additionally, its Average True Range was 0.19.
During the past 100 days, Larimar Therapeutics Inc’s (LRMR) raw stochastic average was set at 5.66%, which indicates a significant decrease from 46.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.75% in the past 14 days, which was higher than the 85.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.6084, while its 200-day Moving Average is $5.7144. Now, the first resistance to watch is $1.9667. This is followed by the second major resistance level at $2.0233. The third major resistance level sits at $2.0767. If the price goes on to break the first support level at $1.8567, it is likely to go to the next support level at $1.8033. The third support level lies at $1.7467 if the price breaches the second support level.
Larimar Therapeutics Inc (NASDAQ: LRMR) Key Stats
The company with the Market Capitalisation of 122.29 million has total of 64,028K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -80,600 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -28,820 K.
